并发TP53突变促进EGFR突变肺腺癌的耐药演化
这项回顾性研究在Dana-Farber癌症研究所纳入269例EGFR突变肺癌患者,采用靶向二代测序分析体细胞突变与临床结局的关联。在185例可评估疗效的患者中,TP53改变与一线无进展生存期和总生存期缩短相关,并与T790M等耐药机制的更快出现相关。
要点
- TP53改变是185例可评估患者中与一线无进展生存期和总生存期缩短相关的最常见事件。
- TP53改变与更快的耐药演化相关,且独立于耐药机制。
- 33例后线奥希替尼治疗中,MET、APC和ERBB4改变与无进展生存期缩短相关。
核心结论
- TP53改变与EGFR突变NSCLC中更快的耐药演化相关,且独立于耐药机制,并可能与其他基因组事件协同介导EGFR酪氨酸激酶抑制剂耐药突变的获得。
研究设计与样本
- 回顾性研究,收集在Dana-Farber癌症研究所治疗的EGFR突变肺癌患者的靶向二代测序数据。
- 共269例患者纳入队列,其中185例有治疗前标本且可评估疗效。
- 分析TP53突变状态、基因组特征与突变过程之间的关联。
主要发现
- 在185例可评估患者中,TP53改变是与一线无进展生存期缩短和总生存期缩短相关的最常见事件,DNMT3A、KEAP1和ASXL1改变亦相关。
- 33例后线奥希替尼治疗患者中,无进展生存期缩短与MET、APC和ERBB4改变相关。
- TP53改变与更差结局相关,即使在初始影像学反应良好的患者中亦然,并与T790M及其他耐药机制的更快获得相关。
- TP53突变肿瘤具有更高的突变负荷,且在治疗和烟草暴露下诱变增加。
- 细胞周期改变并非独立预测因素,但与TP53改变合并时预示更差的总生存期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with EGFR-mutant NSCLC experience variable duration of benefit on EGFR tyrosine kinase inhibitors. The effect of concurrent genomic alterations on outcome has been incompletely described. METHODS: In this retrospective study, targeted next-generation sequencing data were collected from patients with EGFR-mutant lung cancer treated at the Dana-Farber Cancer Institute. Clinical data were collected and correlated with somatic mutation data. Associations between TP53 mutation status, genomic features, and mutational processes were analyzed. RESULTS: A total of 269 patients were identified for inclusion in the cohort. Among 185 response-assessable patients with pretreatment specimens, TP53 alterations were the most common event associated with decreased first-line progression-free survival and decreased overall survival, along with DNMT3A, KEAP1, and ASXL1 alterations. Reduced progression-free survival on later-line osimertinib in 33 patients was associated with MET, APC, and ERBB4 alterations. Further investigation of the effect of TP53 alterations revealed an association with worse outcomes even in patients with good initial radiographic response, and faster acquisition of T790M and other resistance mechanisms. TP53-mutated tumors had higher mutational burdens and increased mutagenesis with exposure to therapy and tobacco. Cell cycle alterations were not independently predictive, but portended worse OS in conjunction with TP53 alterations. CONCLUSIONS: TP53 alterations associate with faster resistance evolution independent of mechanism in EGFR-mutant NSCLC and may cooperate with other genomic events to mediate acquisition of resistance mutations to EGFR tyrosine kinase inhibitors.
引用
- Vokes NI, Chambers E, Nguyen T, et al. Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. J Thorac Oncol. 2022. PMID: 35331964. doi:10.1016/j.jtho.2022.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。